Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy — two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss medications.

Hims had said last week that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month.

Novo immediately threatened to sue, and then the FDA said that it plans to take decisive steps to limit access to the active ingredients in popular GLP-1 drugs like Wegovy, Ozempic and Zepbound.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims said in its statement.

Washington Post publisher steps down

Washington Post publisher Will Lewis said that he’s stepping down, ending a troubled tenure three days after the newspaper said that it was laying off one-third of its staff.

Lewis announced his departure in a two-paragraph email to the newspaper’s staff Saturday, saying that after two years of transformation, “now is the right time for me to step aside.” The Post’s chief financial officer, Jeff D’Onofrio, was appointed temporary publisher.

Neither Lewis nor the newspaper’s billionaire owner Jeff Bezos participated in the meeting with staff members announcing the layoffs. While anticipated, the cutbacks were deeper than expected, resulting in the shutdown of the Post’s renowned sports section, and the elimination of its photography staff.